Hal Martin

3.5k citations

42 papers · 2.8k · 2 hit papers · h-index 24

Impact in

Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
Emergency Medicine top 1%
- HIV-related health complications and treatments

Papers in

Infectious Diseases 42
- HIV/AIDS drug development and treatment 40
- HIV/AIDS Research and Interventions 3
Virology 3
- HIV Research and Treatment 3

Co-authors: Erin K. Quirk (13 shared papers)Xuelian Wei (8 shared papers)Andrew Cheng (8 shared papers)Kirsten White (14 shared papers)Indira Brar (6 shared papers)Paul Edward Sax (9 shared papers)Joseph M. Custodio (4 shared papers)Anthony Mills (5 shared papers)
Journals: JAIDS Journal of Acquired Immune Deficiency Syndromes (8 papers)Open Forum Infectious Diseases (7 papers)The Lancet HIV (7 papers)AIDS (4 papers)The Lancet (2 papers)
Partner nations: United States France Italy

In The Last Decade

Hal Martin

40 papers receiving 2.7k citations

Hal Martin's Hit Papers

align trajectories log scale

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial 2017 · 314 citations

What are hit papers?

Paper score: A paper's citations measured against the top-1% bar of its own field and year: the square root of citations ÷ bar, so 1 means right at the bar and 2 means four times its citations. The bar blends the citation counts that enter the top 1% of the paper's subfields in its year (weighted 89.5%), of those subfields over all years (0.5%) and of its year across all fields (10%); a subfield and year with fewer than 400 papers takes its year's bar. Papers from 2026 are not scored yet: in an unfinished year, when a paper appeared matters more than how it is cited.

Hit paper: A paper cited at least 1.5× the top-1% bar of its field and year: a paper score of at least √1.5.

2017 The Lancet
2015 The Lancet

Peers

Countries citing papers authored by Hal Martin

Since Specialization

Citations

This map shows the geographic impact of Hal Martin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hal Martin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hal Martin more than expected).

Fields of papers citing papers by Hal Martin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hal Martin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hal Martin. The network helps show where Hal Martin may publish in the future.

Co-authors

The 25 scholars most cited alongside Hal Martin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hal Martin Line = papers co-authored together Hal Martin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 42 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials The Lancet ·Paul Edward Sax, David Alain Wohl, Michael T. Yin, Frank Post, Edwin DeJesus, Michael S. Saag, Anton Pozniak, Melanie Thompson Hit paper breakdown →	2015	515
2	Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial The Lancet ·Joel E. Gallant, Adriano Lazzarin, Anthony Mills, Chloe M. Orkin, Daniel Podzamczer, Pablo Tebas, Pierre‐Marie Girard, Indira Brar Hit paper breakdown →	2017	314
3	Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy JAIDS Journal of Acquired Immune Deficiency Syndromes ·Paul Edward Sax, Andrew R. Zolopa, Indira Brar, Richard Elion, Frank Post, Christian Callebaut, Hal Martin, Marshall W. Fordyce	2014	188
4	Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial The Lancet HIV ·Jean‐Michel Molina, Douglas J. Ward, Indira Brar, Anthony Mills, Hans‐Jürgen Stellbrink, Luis Fernando López-Cortés, Peter Jerome Ruane, Daniel Podzamczer	2018	165
5	Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial The Lancet HIV ·Eric S. Daar, Edwin DeJesus, Peter Jerome Ruane, Gordon E. Crofoot, Godson Oguchi, Catherine M. Creticos, Jürgen Kurt Rockstroh, Jean‐Michel Molina	2018	141
6	Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial The Lancet HIV ·David Alain Wohl, Yazdan Yazdanpanah, Axel Baumgarten, Amanda Clarke, Melanie Thompson, Cynthia C Brinson, Debbie P. Hagins, Moti N. Ramgopal	2019	136
7	Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor–Based Single-Tablet Regimen for Initial HIV-1 Therapy JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anthony Mills, Gordon E. Crofoot, Cheryl McDonald, Peter Shalit, Jason Flamm, Joseph Gathe, Anita Scribner, David Shamblaw	2015	135
8	Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate AIDS ·Samir Kumar Gupta, Frank Post, José Ramón Arribas, Joseph J. Eron, David Alain Wohl, Amanda Clarke, Paul Edward Sax, Hans‐Jürgen Stellbrink	2019	134
9	Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials The Lancet HIV ·Chloe M. Orkin, Edwin DeJesus, Paul Edward Sax, José Ramón Arribas, Samir Kumar Gupta, Claudia T. Martorell, Jeffrey L. Stephens, Hans‐Jürgen Stellbrink	2020	112
10	Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial The Lancet HIV ·Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens, Helmut Albrecht, Paul Edward Sax, Franco Maggiolo, Catherine M. Creticos, Claudia T. Martorell	2019	111
11	Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus Clinical Infectious Diseases ·Paul Edward Sax, Jürgen Kurt Rockstroh, Anne F. Luetkemeyer, Yazdan Yazdanpanah, Douglas J. Ward, Benoît Trottier, Armin Rieger, Hui Liu	2020	97
12	Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials Clinical Infectious Diseases ·Kristine Mace Erlandson, Christoph C Carter, Kathleen M. Melbourne, Todd Tarquin Brown, Calvin J. Cohen, Moupali Das, Stefan Esser, Hailin Huang	2021	97
13	Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults JAIDS Journal of Acquired Immune Deficiency Syndromes ·Joel E. Gallant, Melanie Thompson, Edwin DeJesus, Gene W. Voskuhl, Xuelian Wei, Heather Zhang, Kirsten White, Andrew Cheng	2017	85
14	Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial The Lancet HIV ·Paul Edward Sax, Edwin DeJesus, Gordon E. Crofoot, Douglas J. Ward, Paul M. Benson, Robin Henry Dretler, Anthony Mills, Cynthia C Brinson	2017	82
15	Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial JAIDS Journal of Acquired Immune Deficiency Syndromes ·Cissy M Kityo, Debbie P. Hagins, Ellen Koenig, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Khuanchai Supparatpinyo, Natalya Urievna Gankina, Vadim Valentinovich Pokrovsky	2019	53
16	Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I Journal of Antimicrobial Chemotherapy ·Kristen N. Andreatta, Madeleine Willkom, Ross Martin, Silvia Chang, Lilian Wei, Hui Liu, Ya-Pei Liu, Hiba Graham	2019	53
17	Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine Patient ·David Alain Wohl, Amanda Clarke, Franco Maggiolo, Will Garner, Marianne Laouri, Hal Martin, Erin K. Quirk	2018	47
18	Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial Infectious Diseases and Therapy ·Giuliano Rizzardini, Jean‐Michel Molina, Federico Pulido, Stéphane De Wit, Linos Vandekerckhove, Juan Berenguer, Michelle L. D’Antoni, Christiana J. Blair	2021	45
19	Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks Antimicrobial Agents and Chemotherapy ·Rima K Acosta, Madeleine Willkom, Ross Martin, Silvia Chang, Xuelian Wei, William Garner, Justin D. Lutz, Sophia R. Majeed	2019	44
20	Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial The Lancet HIV ·Anchalee Avihingsanon, Hongzhou Lu, Leong Chee Loon, Chien‐Ching Hung, Ellen Koenig, Sasisopin Kiertiburanakul, Man‐Po Lee, Khuanchai Supparatpinyo	2023	43

About Hal Martin

Hal Martin is a scholar working on Infectious Diseases, Virology, Emergency Medicine, Physiology and Nuclear Energy and Engineering, having authored 42 papers that have together received 2.8k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (40 papers), HIV/AIDS Research and Interventions (3 papers), HIV Research and Treatment (3 papers), HIV-related health complications and treatments (2 papers) and Clinical Laboratory Practices and Quality Control (1 paper). The work is most often cited by research in Infectious Diseases (2.3k citations), Emergency Medicine (432 citations), Virology (62 citations), Nephrology (44 citations) and Epidemiology (107 citations). Hal Martin has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Erin K. Quirk, Xuelian Wei, Andrew Cheng, Kirsten White, Indira Brar, Paul Edward Sax, Joseph M. Custodio, Anthony Mills, Jürgen Kurt Rockstroh and Rima K Acosta. Their work appears in journals such as JAIDS Journal of Acquired Immune Deficiency Syndromes, Open Forum Infectious Diseases, The Lancet HIV, AIDS and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Hal Martin

Impact in

Papers in i

In The Last Decade

Hal Martin

Hal Martin's Hit Papers

Peers

Countries citing papers authored by Hal Martin

Fields of papers citing papers by Hal Martin

All Works

About Hal Martin

Explore authors with similar magnitude of impact

Papers in